好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

ATXN2 antisense therapy improves SCA2 mouse motor and Purkinje cell electrophysiological phenotypes.
Movement Disorders
S17 - (-)
001
Authors/Disclosures
Daniel R. Scoles, PhD, FAAN (University of Utah)
PRESENTER
The institution of Dr. Scoles has received research support from NIH.
No disclosure on file
No disclosure on file
Karla P. Figueroa (University of Utah) Ms. Figueroa has nothing to disclose.
No disclosure on file
Frank Bennett, PhD No disclosure on file
Thomas Otis, MD No disclosure on file
Stefan M. Pulst, MD, FAAN (University of Utah) Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for venrock. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arrowhead. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Leverna. Dr. Pulst has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Leninthal LLC. The institution of Dr. Pulst has received research support from NINDS. Dr. Pulst has received intellectual property interests from a discovery or technology relating to health care.